Howe Jill Ann

Chief Financial Officer

Howe Jill Ann has filed 1 SEC Form 4 filing (1 transaction rows) across 1 company, with disclosures dating back to 2026. 1 of those filings fall inside the rolling window. Most recent filing: Nov 16, 2026.

On the most recent filing, Howe Jill Ann is listed as Chief Financial Officer at Lineage Cell Therapeutics, Inc. Inside the rolling window, Howe Jill Ann reported 1 open-market purchase totaling $17K in LCTX and no open-market sales.

Companies traded

Other insiders at LCTX

Insider Buying

$17K

reported purchases (SEC code P)

Insider Selling

$0

reported sales (SEC code S)

Companies

1

in the rolling window

Source
LCTXPurchase$17KNov 16SEC ↗
Showing 1–1 of 1
1 / 1

Frequently asked questions

How many SEC Form 4 filings has Howe Jill Ann made?

Howe Jill Ann has filed 1 SEC Form 4 filing (1 transaction rows) across 1 company since 2026.

Which companies does Howe Jill Ann trade?

Howe Jill Ann has filed SEC Form 4 disclosures for 1 company, including LCTX.

When was Howe Jill Ann's most recent SEC Form 4 filing?

Howe Jill Ann's most recent SEC Form 4 filing on Tracefour is dated Nov 16, 2026.

What is Howe Jill Ann's job title?

On the most recent SEC Form 4 filings tracked by Tracefour, Howe Jill Ann is listed as Chief Financial Officer.

What is Howe Jill Ann's total buy and sell value in the current window?

Inside the rolling retention window, Howe Jill Ann bought $17K and sold $0 based on SEC Form 4 filings.

What was Howe Jill Ann's largest disclosed transaction?

The largest disclosed transaction in the current window is a purchase of 20,000 LCTX shares on 2026-11-16, worth $17K, per SEC Form 4 filings.